{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:07:13Z","timestamp":1773410833707,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2490-12-19","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T14:45:23Z","timestamp":1343313923000},"source":"Crossref","is-referenced-by-count":17,"title":["Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study"],"prefix":"10.1186","volume":"12","author":[{"given":"David","family":"Castro-Diaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Sanchez-Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Lizarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Arum\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rejas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"225_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van KP, Victor A, Wein A: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002, 21: 167-178. 10.1002\/nau.10052.","journal-title":"Neurourol Urodyn"},{"key":"225_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/nau.20737","volume":"28","author":"P Abrams","year":"2009","unstructured":"Abrams P, Artibani W, Cardozo L, Dmochowski R, Van KP, Sand P: Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009, 28: 287-10.1002\/nau.20737.","journal-title":"Neurourol Urodyn"},{"key":"225_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","volume":"60","author":"AJ Wein","year":"2002","unstructured":"Wein AJ, Rovner ES: Definition and epidemiology of overactive bladder. Urology. 2002, 60: 7-12.","journal-title":"Urology"},{"key":"225_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/TCRM.S6483","volume":"5","author":"P Ellsworth","year":"2009","unstructured":"Ellsworth P: Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009, 5: 869-876.","journal-title":"Ther Clin Risk Manag"},{"key":"225_CR5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ: Prevalence and burden of overactive bladder in the United States. World J Urol. 2003, 20: 327-336.","journal-title":"World J Urol"},{"key":"225_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006, 50: 1306-1314. 10.1016\/j.eururo.2006.09.019.","journal-title":"Eur Urol"},{"key":"225_CR7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001, 87: 760-766.","journal-title":"BJU Int"},{"key":"225_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1742-1241.2009.02035.x","volume":"63","author":"JJ Wyndaele","year":"2009","unstructured":"Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Guan Z, Choo MS: Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009, 63: 560-567. 10.1111\/j.1742-1241.2009.02035.x.","journal-title":"Int J Clin Pract"},{"key":"225_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4321\/S0004-06142005000200006","volume":"58","author":"D Castro","year":"2005","unstructured":"Castro D, Espuna M, Prieto M, Badia X: Prevalence of overactive bladder in Spain: a population-based study. Arch Esp Urol. 2005, 58: 131-138.","journal-title":"Arch Esp Urol"},{"key":"225_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0210-4806(09)74117-8","volume":"33","author":"AE Martinez","year":"2009","unstructured":"Martinez AE, Ruiz Cerda JL, Gomez PL, Ramirez BM, Delgado OF, Rebollo P, Gonzalez-Segura AD, Arumi D: [Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study]. Actas Urol Esp. 2009, 33: 159-166.","journal-title":"Actas Urol Esp"},{"key":"225_CR11","first-page":"S580","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams P, Kelleher CJ, Kerr LA, Rogers RG: Overactive bladder significantly affects quality of life. Am J Manag Care. 2000, 6: S580-S590.","journal-title":"Am J Manag Care"},{"key":"225_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","volume":"57","author":"JN Liberman","year":"2001","unstructured":"Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Lipton RB, Diokno AC: Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001, 57: 1044-1050. 10.1016\/S0090-4295(01)00986-4.","journal-title":"Urology"},{"key":"225_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","volume":"7","author":"KS Coyne","year":"2004","unstructured":"Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, Hunt TL: The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004, 7: 455-463. 10.1111\/j.1524-4733.2004.74008.x.","journal-title":"Value Health"},{"key":"225_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1100\/tsw.2009.55","volume":"9","author":"B Patel","year":"2009","unstructured":"Patel B, Bavendam T, Badlani G: Use of antimuscarinics in the elderly. ScientificWorldJournal. 2009, 9: 459-465.","journal-title":"ScientificWorldJournal"},{"key":"225_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMra032662","volume":"350","author":"JG Ouslander","year":"2004","unstructured":"Ouslander JG: Management of overactive bladder. N Engl J Med. 2004, 350: 786-799. 10.1056\/NEJMra032662.","journal-title":"N Engl J Med"},{"key":"225_CR16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.18553\/jmcp.2008.14.3.291","volume":"14","author":"AO D'Souza","year":"2008","unstructured":"D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R: Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008, 14: 291-301.","journal-title":"J Manag Care Pharm"},{"key":"225_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2165\/00044011-200929050-00003","volume":"29","author":"SE Swift","year":"2009","unstructured":"Swift SE, Siami P, Forero-Schwanhaeuser S: Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4\u2009mg\/day to solifenacin treatment: an open-label, flexible-dosing, multicentre study. Clin Drug Investig. 2009, 29: 305-316. 10.2165\/00044011-200929050-00003.","journal-title":"Clin Drug Investig"},{"key":"225_CR18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1464-410X.2010.09640.x","volume":"107","author":"SA Kaplan","year":"2011","unstructured":"Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J: Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011, 107: 1432-1440. 10.1111\/j.1464-410X.2010.09640.x.","journal-title":"BJU Int"},{"key":"225_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","volume":"105","author":"S Herschorn","year":"2010","unstructured":"Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010, 105: 58-66. 10.1111\/j.1464-410X.2009.09086.x.","journal-title":"BJU Int"},{"key":"225_CR20","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/j.1742-1241.2008.01893.x","volume":"62","author":"N Zinner","year":"2008","unstructured":"Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P: Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract. 2008, 62: 1664-1674. 10.1111\/j.1742-1241.2008.01893.x.","journal-title":"Int J Clin Pract"},{"key":"225_CR21","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1464-410X.2008.07907.x","volume":"102","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Van Kerrebroeck PE, Junemann KP, Wang JT, Brodsky M: Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008, 102: 1128-1132. 10.1111\/j.1464-410X.2008.07907.x.","journal-title":"BJU Int"},{"key":"225_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.urology.2007.12.017","volume":"71","author":"V Khullar","year":"2008","unstructured":"Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z: Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008, 71: 839-843. 10.1016\/j.urology.2007.12.017.","journal-title":"Urology"},{"key":"225_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.urology.2009.09.018","volume":"75","author":"RR Dmochowski","year":"2010","unstructured":"Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, Siami P, Staskin DR: Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010, 75: 62-68. 10.1016\/j.urology.2009.09.018.","journal-title":"Urology"},{"key":"225_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11934-003-0025-z","volume":"4","author":"SA MacDiarmid","year":"2003","unstructured":"MacDiarmid SA: Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep. 2003, 4: 446-451. 10.1007\/s11934-003-0025-z.","journal-title":"Curr Urol Rep"},{"key":"225_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","volume":"49","author":"JG Malone-Lee","year":"2001","unstructured":"Malone-Lee JG, Walsh JB, Maugourd MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001, 49: 700-705. 10.1046\/j.1532-5415.2001.49144.x.","journal-title":"J Am Geriatr Soc"},{"key":"225_CR26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0022-5347(05)64567-3","volume":"168","author":"MC Michel","year":"2002","unstructured":"Michel MC, Schneider T, Krege S, Goepel M: Does gender or age affect the efficacy and safety of tolterodine?. J Urol. 2002, 168: 1027-1031. 10.1016\/S0022-5347(05)64567-3.","journal-title":"J Urol"},{"key":"225_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1046\/j.1532-5415.2002.50203.x","volume":"50","author":"NR Zinner","year":"2002","unstructured":"Zinner NR, Mattiasson A, Stanton SL: Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002, 50: 799-807. 10.1046\/j.1532-5415.2002.50203.x.","journal-title":"J Am Geriatr Soc"},{"key":"225_CR28","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1185\/03007X226294","volume":"23","author":"C Chapple","year":"2007","unstructured":"Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A: Darifenacin treatment of patients\u2009>\u2009or\u2009=\u200965\u2009years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007, 23: 2347-2358. 10.1185\/03007X226294.","journal-title":"Curr Med Res Opin"},{"key":"225_CR29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.urology.2010.03.097","volume":"76","author":"SR Kraus","year":"2010","unstructured":"Kraus SR, Ruiz-Cerda JL, Martire D, Wang JT, Wagg AS: Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology. 2010, 76: 1350-1357. 10.1016\/j.urology.2010.03.097.","journal-title":"Urology"},{"key":"225_CR30","volume-title":"Pharmacoepidemiology","author":"PD Stolley","year":"2000","unstructured":"Stolley PD, Laporte J: The Public Health, the University, and Pharmacoepidemiology. Pharmacoepidemiology. Edited by: Strom BL. 2000, John Wiley & Sons, Third","edition":"Third"},{"key":"225_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1526-4637.2004.04036.x","volume":"5","author":"RM Gallagher","year":"2004","unstructured":"Gallagher RM: Naturalistic study designs in samples with refractory pain: advantages and limitations. Pain Med. 2004, 5: 143-145. 10.1111\/j.1526-4637.2004.04036.x.","journal-title":"Pain Med"},{"key":"225_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.acuro.2010.11.011","volume":"35","author":"D Castro","year":"2011","unstructured":"Castro D, Miranda P, Sanchez-Ballester F, Arumi D, Lizarraga I, Ebel C: Assessment of reasons for overactive bladder treatment change. Actas Urol Esp. 2011, 35: 73-79. 10.1016\/S2173-5786(11)70022-1.","journal-title":"Actas Urol Esp"},{"key":"225_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/BF02850085","volume":"22","author":"KS Coyne","year":"2005","unstructured":"Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG: Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther. 2005, 22: 381-394. 10.1007\/BF02850085.","journal-title":"Adv Ther"},{"key":"225_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.urology.2008.05.033","volume":"72","author":"S Colman","year":"2008","unstructured":"Colman S, Chapple C, Nitti V, Haag-Molkenteller C, Hastedt C, Massow U: Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology. 2008, 72: 803-807. 10.1016\/j.urology.2008.05.033.","journal-title":"Urology"},{"key":"225_CR35","first-page":"218","volume-title":"Clinical Global Impressions: In ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM)","author":"W Guy","year":"1976","unstructured":"Guy W: Clinical Global Impressions: In ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). 1976, Rockville, MDL: National Institute for Mental Health, 218-222."},{"key":"225_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986, 24: 67-74. 10.1097\/00005650-198601000-00007.","journal-title":"Med Care"},{"key":"225_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","volume":"4","author":"A Wagg","year":"2006","unstructured":"Wagg A, Wyndaele JJ, Sieber P: Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006, 4: 14-24. 10.1016\/j.amjopharm.2006.03.004.","journal-title":"Am J Geriatr Pharmacother"},{"key":"225_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0009-9236(98)90104-7","volume":"63","author":"N Brynne","year":"1998","unstructured":"Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J: Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998, 63: 529-539. 10.1016\/S0009-9236(98)90104-7.","journal-title":"Clin Pharmacol Ther"},{"key":"225_CR39","doi-asserted-by":"publisher","first-page":"570","DOI":"10.5414\/CPP47570","volume":"47","author":"BK Malhotra","year":"2009","unstructured":"Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009, 47: 570-578.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"225_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S1569-9056(11)60864-6","volume":"10","author":"A Wagg","year":"2011","unstructured":"Wagg A, Khullar V, Marschall-Kehrel D, et al: Assessment of fesoterodine treatmetn in older people with overactive bladder: result of SOFIA, a double blind, placebo-controlled pan European trial. Eur Urol Supplement. 2011, 10: 276-277. [abstract]. e 2011","journal-title":"Eur Urol Supplement"},{"key":"225_CR41","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","volume":"52","author":"C Chapple","year":"2007","unstructured":"Chapple C, Van KP, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007, 52: 1204-1212. 10.1016\/j.eururo.2007.07.009.","journal-title":"Eur Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2490-12-19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-12-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-12-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-12-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T03:16:50Z","timestamp":1642907810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/1471-2490-12-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1186\/1471-2490-12-19","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]},"article-number":"19"}}